Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
89Zr-rituximab PET/CT for Detection of Central Nervous System Lymphoma
2015-000056-23Phase 2Active
- Sponsor
- University Medical Center Utrecht
- Start
- Jun 2015
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 89Zr-rituximab in central nervous system lymphoma and primary central nervous system lymphoma (PCNSL), sponsored by University Medical Center Utrecht. Primary endpoint: Diagnostic performance of 89Zr-rituximab PET/CT for CNS lymphoma. Started Jun 2015; status: active.
02
Drugs
89Zr-rituximab
03
Conditions
central nervous system lymphomaprimary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on 2015-000056-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000056-23.